Fed Governor Cook sues Trump over firing attempt
In a recent filing with the Securities and Exchange Commission, Humacyte Inc. (NASDAQ:HUMA) Director Michael T. Constantino disclosed the purchase of 16,000 shares of the company's common stock. The shares were acquired on April 7, 2025, at a weighted average price of $1.26 per share, amounting to a total transaction value of $20,160. According to InvestingPro data, the stock currently trades at $1.15, near its 52-week low of $1.18, with analyst price targets ranging from $3 to $25.
The purchase increases Constantino's direct ownership to 32,950 shares following the transaction. The shares were bought in multiple transactions at prices ranging from $1.255 to $1.26 per share. This acquisition highlights Constantino's continued investment in the Durham, North Carolina-based biotechnology company, which specializes in developing human tissue-based products. InvestingPro analysis shows the company maintains strong liquidity with a current ratio of 2.4, though it faces challenges with cash burn. Discover 10+ additional exclusive insights and detailed financial metrics with InvestingPro's comprehensive research report.
In other recent news, Humacyte reported a narrower fourth-quarter loss of $0.16 per share, surpassing analyst estimates of a $0.25 per share loss. Despite this, the company generated no revenue for the quarter, consistent with the previous year's results. This comes after the FDA approved Humacyte's vascular graft product, Symvess, in December, with the commercial launch beginning in late February. The company shipped its first units to two Level 1 trauma centers, and 34 hospitals have started the approval process to purchase Symvess. Humacyte ended 2024 with $95.3 million in cash and raised an additional $46.6 million through a public stock offering in March 2025. Benchmark analysts maintained a Buy rating with a $17 target, citing the company's strategic plans and ongoing product traction. BTIG analyst Ryan Zimmerman also maintained a Buy rating but lowered the price target from $10.00 to $8.00, noting the early commercial traction of Humacyte's product. Humacyte plans to file an IND application in 2025 for coronary artery bypass grafting and a supplemental application in late 2026 for expanded uses of Symvess.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.